Y. Li

Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib

H. Horinouchi, B.C. Cho, D. Ross Camidge, Kōichi Goto et autres

BACKGROUND: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein …

jp, kr, us, fr (code pays fourni par la source)

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results

Amy Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart et autres

us (code pays fourni par la source)

515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates

H. Horinouchi, B.C. Cho, D. Ross Camidge, Kōichi Goto et autres

kr, us, jp, fr (code pays fourni par la source)

322MO Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2

Byoung Chul Cho, Youjie Wang, Y. Li, L. Wu et autres

kr, cn, fr, us, jp (code pays fourni par la source)